Purchase Short-Term Access

Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents: A Cost-Effectiveness Analysis
Axel Finckh, MD, MS; Nick Bansback, MS; Carlo A. Marra, PharmD, PhD; Aslam H. Anis, PhD; Kaleb Michaud, PhD; Stanley Lubin, MD; Marc White, PhD; Sonia Sizto, BA; Matthew H. Liang, MD, MPH
Annals of Internal Medicine 2009;151:612-621. doi:10.7326/0003-4819-151-9-200911030-00006

Purchase Online access to this article for 24 hours
Buy Now for $32.00
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.